Latest Royalties News

Lode Resources has agreed to sell its Webbs Consol Silver Project to Rapid Critical Metals for A$3.75 million in cash, a significant shareholding, and a royalty, positioning both companies for strategic growth in New South Wales.

Rapid Critical Metals is set to become Australia's highest grade silver company through its acquisition of the Webbs Consol Silver Project, expanding its resource base to approximately 67 million ounces of silver equivalent at exceptional grades.

Tamboran Resources has secured a pioneering approval from the Northern Territory Government to sell appraisal gas from its Beetaloo Basin exploration permits, marking a significant step toward local energy supply and revenue generation.

Fenix Resources has locked in exclusive 30-year mining rights over a 290 million tonne iron ore resource at the Weld Range Project, significantly extending its mine life and production capacity. This strategic partnership with Sinosteel Midwest and Baowu Steel Group positions Fenix for ambitious growth in Western Australia's Mid-West.

PT Aneka Tambang Tbk (ANTAM) reported a remarkable 240% surge in net profit for the half year ended June 30, 2025, driven by robust gold and nickel sales amid a challenging mining sector.

Opthea Limited reported a 26% reduction in net loss for FY2025 despite discontinuing its wet AMD drug after failed Phase III trials. The company settled its Development Funding Agreement with investors, securing liquidity and planning a strategic pivot.

Botanix Pharmaceuticals posted a sharp revenue increase driven by its new hyperhidrosis treatment Sofdra, yet reported a substantial net loss reflecting heavy investment in commercialisation. The company’s strong cash position underpins its path to profitability.

4DS Memory Limited posted a $9.68 million loss for FY2025 as it advanced its 20nm ReRAM technology, encountering manufacturing setbacks that prompted a detailed root cause analysis. The company secured $8 million in capital to support ongoing development and strategic partnerships.

Burgundy Diamond Mines posted a $29.5 million net loss for H1 2025, driven by operational disruptions and weaker diamond prices, leading to a temporary halt of mining at Point Lake. The company is navigating liquidity challenges with new financing arrangements while restructuring its operations.

Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.

Macarthur Minerals Limited reported a successful capital raise and key strategic partnerships at its 2025 AGM, positioning itself for future growth in iron ore production.

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.